Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PersAFOne II(Pronounced Per-'Se-fa-nē 2); Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation

NCT05152966 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT05152966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05152966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PersAFOne II(Pronounced Per-'Se-fa-nē 2); Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Completed
Start date
September 16, 2021
Completion date
December 1, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

persistent atrial fibrillation